Greetings everyone, here is your digest of February Newsletters, HCV publications, today's news and updates from devoted bloggers around the web. To start you off we have a few highlights of today's post...
Highlights
Raymond Schinazi a former Veterans Affairs Department scientist defends his reputation against the allegations he earned millions after selling a hepatitis C treatment he invented using agency resources to a private company, read the article at military.com; Former VA Scientist Responds to Lawmaker's Suspicions over Drug Sale.
As for newsletters Lucinda K. Porter's article in this months issue of HCV Advocate offer us some insight into generic HCV drugs sold from outside the United States; HealthWise—Generic Hepatitis C Drugs.
HealthNewsReview published a review summary on Merck’s Hep C newly approved drug Zepatier (elbasvir and grazoprevir), here is an excerpt
The release seems targeted primarily to healthcare professionals, rather than consumers, so it’s chock-full of jargon and statistics. While the release indicates the risks, benefits and costs, we saw some weaknesses in the presentation of the evidence.
Related:
Resistance Testing is Recommended Prior to Merck Zepatier Treatment Only for Genotype 1a
Over at Clinical Liver Disease a review of Daclatasvir in combination with sofosbuvir in HCV genotype 3 is explored; Integrating daclatasvir into hepatitis c therapy.
Resistance Testing is Recommended Prior to Merck Zepatier Treatment Only for Genotype 1a
Over at Clinical Liver Disease a review of Daclatasvir in combination with sofosbuvir in HCV genotype 3 is explored; Integrating daclatasvir into hepatitis c therapy.
One of my favorite bloggers Karen Hoyt shares her expertise on hepatitis C and skin issues; Dry Itching Skin Solutions. After reading Karen's article you may be interested in jumping back to Clinical Liver Disease to review; Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic.
Today Bristol-Myers announced that the FDA has approved Expanded Use for Daklinza (daclatasvir) in combination with sofosbuvir with or without ribavirin to treat HCV genotypes 1 and 3.
The expanded indication for Daklinza offers an additional treatment option for multiple subsets of patients who have genotype 1 or 3 chronic HCV,” said Chris Boerner, Head of U.S. Commercial, Bristol-Myers Squibb. Indication
The press release including changes to the Daklinza (daclatasvir) label expand indication outlined by the FDA:
February 05, 2016
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza™(daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without ribavirin) in genotypes 1 and 3. The expanded label includes data in three additional challenging-to-treat patient populations: chronic hepatitis C virus (HCV) patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV. The Daklinza plus sofosbuvir regimen is already available for the treatment of chronic HCV genotype 3, and is currently the only 12-week, once-daily all-oral treatment option for these patients. Sustained virologic response (SVR) rates are reduced in genotype 3 patients with cirrhosis receiving Daklinza and sofosbuvir for 12 weeks without ribavirin. The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir with or without (+/-) ribavirin for 12 weeks.
Other news tidbits to get you started...
THE fight against liver disease in Wales has been boosted by a £2.4 million investment from the Welsh Government.
Deaths from liver disease in Wales have more than doubled over the past 20 years as a result of the rise in obesity, alcohol misuse and viral hepatitis.
Feb 5
Former VA Scientist Responds to Lawmaker's Suspicions over Drug Sale
A former Veterans Affairs Department scientist says he is willing and able to defend his reputation against lawmakers or others who suggest he invented a highly successful hepatitis C treatment using agency resources and later earned millions by selling it to a private company.Deaths from liver disease in Wales have more than doubled over the past 20 years as a result of the rise in obesity, alcohol misuse and viral hepatitis.
Feb 5
Former VA Scientist Responds to Lawmaker's Suspicions over Drug Sale
The drug shown to cure hepatitis C is sold by Gilead Sciences of California under the brand name Sovaldi, but it was developed at Pharmasset, a private lab owned by Dr. Raymond Schinazi while he worked for the VA Medical Center in Atlanta and Emory University.
Today, skeptical lawmakers question whether Schinazi got rich using VA resources and funding. He sold Pharmasset, and with it the drug, to Gilead in 2011 for $11 billion.
Congress outraged over hepatitis C treatment VA can't afford
WASHINGTON -- Congress is looking into why veterans are being denied a cure for a deadly form of hepatitis. In a CBS News investigation, we told you the cure was developed by a doctor working for the Department of Veterans Affairs.
WASHINGTON -- Congress is looking into why veterans are being denied a cure for a deadly form of hepatitis. In a CBS News investigation, we told you the cure was developed by a doctor working for the Department of Veterans Affairs.
Baystate Health releases internal report on 293 patients potentially exposed to hepatitis, HIV
Hep C nurse excited about new drug
Published on: February 5, 2016 | Last Updated: February 5, 2016 4:00 AM CST
A new drug to treat hepatitis C has Lesley Gallagher excited for patients’ futures.
“Anything that brings attention to hepatitis C today and stresses the importance of being diagnosed, being assessed, being aware, is really important,” said Gallagher, a treatment support nurse in Saskatoon and Vancouver.
Drug company Merck announced Wednesday that Zepatier is now available in Canada.
MassLive.com
... patients, and there was no escalation that would have included both the hospital epidemiologist and senior leadership." The exposed patients have been notified that they should be screened for hepatitis B, hepatitis C and HIV, the virus that causes ...
How Do Pharmaceutical Companies Establish Drug Prices?
... patients, and there was no escalation that would have included both the hospital epidemiologist and senior leadership." The exposed patients have been notified that they should be screened for hepatitis B, hepatitis C and HIV, the virus that causes ...
How Do Pharmaceutical Companies Establish Drug Prices?
Drug companies are under increasing pressure to keep prices under control. At a hearing on Capitol Hill Thursday, lawmakers from both sides of the aisle blasted two companies that have instituted huge price increases. NPR explores how drug companies establish prices for a drug.
Hep C nurse excited about new drug
Published on: February 5, 2016 | Last Updated: February 5, 2016 4:00 AM CST
A new drug to treat hepatitis C has Lesley Gallagher excited for patients’ futures.
“Anything that brings attention to hepatitis C today and stresses the importance of being diagnosed, being assessed, being aware, is really important,” said Gallagher, a treatment support nurse in Saskatoon and Vancouver.
Drug company Merck announced Wednesday that Zepatier is now available in Canada.
80% of liver cancer deaths can be prevented, saving hundreds of thousands of lives each year globally
4 Feb 2016 Tara Farrell
On World Cancer Day, the World Hepatitis Alliance is calling for the establishment of comprehensive hepatitis strategies to help prevent the 800,000
4 Feb 2016 Tara Farrell
On World Cancer Day, the World Hepatitis Alliance is calling for the establishment of comprehensive hepatitis strategies to help prevent the 800,000
February 3, 2016
A new capture-fusion assay was accurate in testing sensitivity of different antiviral drugs, suggesting it may be effective for determining treatment strategies for patients with hepatitis C virus infection.
“We have developed a capture-fusion assay that permits replication of patient-derived HCV of all vital genotypes in vitro and enables testing of sensitivity to antiviral drugs. … [It] may help identify the most appropriate treatment strategy for patients with chronic HCV,” the researchers wrote.
In-depth Merck release on new Hep C drug skirts some of the basics
What is HealthNewsReview.org?
The mission of HealthNewsReview.org is to improve the public dialogue about health care by helping consumers critically analyze claims about health care interventions and by promoting the principles of shared decision-making reinforced by accurate, balanced and complete information about the tradeoffs involved in health care decisions. HealthNewsReview.org evaluates health care journalism, advertising, marketing, public relations and other messages that may influence consumers and provides criteria that consumers can use to evaluate these messages themselves. Improving the quality and flow of health care news and information to consumers can be a significant step towards meaningful health care reform.
Blog
Website
In-depth Merck release on new Hep C drug skirts some of the basics
Our Review Summary
Merck’s PR release fills us in on its freshly FDA-approved drug — Zepatier (elbasvir and grazoprevir) — to treat two different forms of hepatitis C and claims to “cure” upwards of 94% of infections based on 12- and 16-week trials. The combination pill is taken once a day throughout treatment. The release seems targeted primarily to healthcare professionals, rather than consumers, so it’s chock-full of jargon and statistics. While the release indicates the risks, benefits and costs, we saw some weaknesses in the presentation of the evidence. For example, the news release did not provide the outcomes for the placebo group, even though the studies compared the drugs with placebo. Nor did it explain that the outcome assessed — sustained virologic response — is a short-term proxy for the longer-term results that patients really care about, such as rates of liver failure and cancer.
Speaking of costs, what this release doesn’t cover (although who would expect a for-profit drug company to do so?) is the insane cost of specialty drugs, the rising demand for them, and their increasing burden on the U.S. healthcare system. HealthNewsReview.org contributor Trudy Lieberman expands on this issue in a recent blog post, which happens to focus on another (very expensive) hepatitis C drug.
HCV Advocate
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.
February Newsletter
This month’s edition of the HCV Advocate newsletter has the following articles:
In Memory of Jacques Chambers – a member of the HCV Advocate family has died after a brief illness. Read about Jacques and his many contributions to the HCV Advocate and the other communities.
HealthWise—Generic Hepatitis C Drugs –Lucinda K. Porter RN writes about the pros and cons of generic Hep C drugs so you can make an educated choice about whether or not you want to go the generic route.
SnapShots—I write about the influence of gender on HCV disease progression, treatment with sofosbuvir plus daclatasvir to treat people with HIV/HCV coinfection and the prevalence of HIV, HBV and HCV among people with severe mental illness.
HCSP Training Workshops – 2002 – 2015 – the training workshops have come to an end. I write a short recap of our training workshop history including the best and worst of my experiences on the road.
What’s Up – we have updated A Guide to Understanding HCV 2016.
We also discuss changes to our three blogs:
HCV News and Pipeline Blog
HBV Blog
Official Blog of the Hepatitis and Tattoo Website.
Note: If you are currently a Google/Blogger follower, you will no longer be receiving the updates you are used to receiving. We’d like to keep you updated, so please “Follow by Email” on the new blog after February 1; or simply use the old blog address when you want to see the latest posts and you will be redirected.
Click here to read this issue.
Welcome to the January/February 2016 edition of the Liver Lowdown. Click on the links below and check out our featured stories for the month!
Newsletter
January/February
INTRO/FEATURE OF THE MONTH
Happy 2016 and welcome to our first Liver Lowdown newsletter of 2016. This marks our 40th year serving the liver community, so this issue will focus on a topic that is near and dear to us: Research.
READ MORE
LIVER MEETING- INTRO AND NAFLD/NASH NEWS
Americans know little about the liver. See the statistics. On the other hand, scientists are learning more about conditions like Fatty Liver Disease every day.
READ MORE
LIVER MEETING- PSC AND PBC NEWS
Read more about Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) advancements presented at the Liver Meeting.
READ MORE
LIVER MEETING- LIVER TRANSPLANT NEWS, ADDITIONAL FINDINGS AND CLOSING
Interesting takeaways about liver transplants, cirrhosis and the health benefits of coffee.
READ MORE
CALENDAR OF EVENTS
As we start the new year, we've got a variety of events planned around the country. Find out what's going on near you!
READ MORE
RECIPE OF THE MONTH
Looking for an interesting recipe to try out? We've got you covered, with a vegan and gluten-free option from one of our Flavors chefs that's sure to tantalize your taste buds!
READ MORE
To receive the newsletter when it's "hot off the press" please join our email list.
View all newsletters, here.
Join Us
GI & Hepatology News
GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
GI & Hepatology Newsletter
February 2016 PDF ( 4.2MB)
FDA approves new treatment for chronic HCV genotypes 1 and 4
By: RICHARD PIZZI
01/29/16
The U.S. Food and Drug Administration has approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections in adults.
HCV Action brings together hepatitis C health professionals from across the patient pathway with the pharmaceutical industry and patient representatives to share expertise and good practice.
HCV Action e-update: January 2016
04 Feb 2016
HCV Action have published two new case studies, both of which highlight innovative ways of ensuring that more people are diagnosed, tested and treated for hepatitis C.
LATEST NEWS FROM THE HEPATITIS C TRUST
Be the voice of people living with hepatitis C
View newsletter archive
Connect With Us On Twitter
Blogs Around The Web
Daryl Luster - President of Pacific Hepatitis C Network. Advocate for people living with HCV.
Writing Your HCV StoryLIVING
By Daryl Luster - February 2, 2016
Not all of us feel comfortable sharing our hepatitis c story with the world. There are a number of reasons why people do not disclose their status beyond those close to them,...READ MORE
Step by Step or One Day at a TimeLIVING
By Daryl Luster - January 28, 2016
In history there have been many versions of what these words mean, and here in the context of dealing with HCV we use them also. Several examples can be found in popular... READ MORE
The Power of HopeLIVING
By Daryl Luster - January 25, 2016
On doing a little research before writing this, I was looking into the origins of the word hope, and I learned something. It was said in one account that it was from... READ MORE
Judgment and AcceptanceLIVING
By Daryl Luster - January 14, 2016
As we have all heard many times, and possibly said before, it is wrong to judge others. It is certainly a noble pursuit not to judge, but in reality we do it,... READ MORE
VIEW ALL POSTS BY DARYL LUSTER
Foods that are Good for Your LiverLIVING
By Jenelle Marie Davis - February 4, 2016
Why it Matters? The liver is an incredibly vital organ – so much so that the body cannot survive without it. Two of its primary functions are to work with your blood... READ MORE
Dry Itching Skin SolutionsLIVING
By Karen Hoyt - February 3, 2016
Believe me, I understand that feeling. It is more than just dry skin. It is an itching sensation that can drive you a little bit batty at times. One of the symptoms... READ MORE
Socially accessible
We’re active on your social network.
HEPATITISC.NET ON TWITTER
HEPATITISC.NET ON FACEBOOK
HEPATITISC.NET ON GOOGLE+
About Karen Hoyt
Karen Hoyt offers a no nonsense approach to living with Cirrhosis. A Hepatitis C treatment survivor, she created a liver loving diet and lifestyle that allows her to create awareness and advocate for her Best Friends at http://www.ihelpc.com
Courage and Confidence with Liver Cancer
During my battle with liver cancer, I loved reading all of your personal cards, emails, and messages. How could I possibly respond back? (Picture me typing all night.) Instead, I folded strong words into my heart and recited them to me when I needed them. (Daily, hourly) Little love letters.One morning after my liver transplant, while poring over more of your emails and messages, one word kept popping up – Brave. I remember my face felt hot. I didn’t feel brave at all. I was terrified. I needed courage and confidence with liver cancer.
Continue reading....
The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure for hepatitis B and helping to improve the lives of those affected worldwide through research, education and patient advocacy. Visit www.hepb.org
Can People with HBeAg-Negative Hepatitis B Ever Stop Taking Antivirals?
In this week’s blog, we explore when—if ever—individuals with hard-to-treat HBeAg-negative hepatitis B can ever stop taking antivirals.
by LUCINDA PORTER
Welcome to my website and blog. My name is Lucinda Porter and I am a nurse committed to raising awareness about hepatitis C. I believe that we can create a world free of hepatitis C. We do this together, one step at a time.
World Cancer Day: Curing Hep C is One Way to Prevent Liver Cancer
by LUCINDA PORTER on FEBRUARY 4, 2016
Today is World Cancer Day. Below is a press release from the World Hepatitis Alliance. Their words are better than anything I could say…
Lucinda K. Porter, RN
Marsha Williams
A story about living with hep C, fatigue, anemia cirrhosis and more...
February 5, 2016
A new capture-fusion assay was accurate in testing sensitivity of different antiviral drugs, suggesting it may be effective for determining treatment strategies for patients with hepatitis C virus infection.
“We have developed a capture-fusion assay that permits replication of patient-derived HCV of all vital genotypes in vitro and enables testing of sensitivity to antiviral drugs. … [It] may help identify the most appropriate treatment strategy for patients with chronic HCV,” the researchers wrote.
Kentucky goes to battle against Hepatitis C and HIV
The Eastern Progress Online (subscription) - 22 hours ago
Currently, the Bluegrass state is battling a new, addictive enemy of public health. Over the past few years, heroin has become the drug of choice in Kentucky, allowing users a good high for a relatively low rate.
The Eastern Progress Online (subscription) - 22 hours ago
Currently, the Bluegrass state is battling a new, addictive enemy of public health. Over the past few years, heroin has become the drug of choice in Kentucky, allowing users a good high for a relatively low rate.
By ED SILVERMAN @Pharmalot
The lawsuits, which were filed late last month in state court and seek class action status, charge that Group Health Cooperative and BridgeSpan restricted access to the medicines except to the “most severely ill” people, but not for a “clinical purpose.” Instead, the consumers charge the insurers do so due to “financial concerns.” And they want the insurers to provide coverage.
BridgeSpan requires “infected individuals wait for treatment — potentially for years — until they demonstrate serious scarring or cirrhosis of the liver from hepatitis C infection,” one lawsuit charges. Meanwhile, patients are “forced to live with … an increased risk of cancer or death.” The lawsuit pointed to criteria for the coverage decision made by.....
The lawsuits, which were filed late last month in state court and seek class action status, charge that Group Health Cooperative and BridgeSpan restricted access to the medicines except to the “most severely ill” people, but not for a “clinical purpose.” Instead, the consumers charge the insurers do so due to “financial concerns.” And they want the insurers to provide coverage.
BridgeSpan requires “infected individuals wait for treatment — potentially for years — until they demonstrate serious scarring or cirrhosis of the liver from hepatitis C infection,” one lawsuit charges. Meanwhile, patients are “forced to live with … an increased risk of cancer or death.” The lawsuit pointed to criteria for the coverage decision made by.....
Publications
In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with hepatitis C virus infection post-liver transplant and with advanced liver disease.
Daily coffee consumption may reduce risk for cirrhosis
In a systematic review and meta-analysis, researchers in the UK found that increased coffee consumption reduced the risk for cirrhosis, according to published findings in Alimentary Pharmacology and Therapeutics.
In a systematic review and meta-analysis, researchers in the UK found that increased coffee consumption reduced the risk for cirrhosis, according to published findings in Alimentary Pharmacology and Therapeutics.
To assess the current frequency of ART-associated grade 3–4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE) in HIV-infected patients with chronic hepatitis B and/or C, who start a new regimen of ART.
In-depth Merck release on new Hep C drug skirts some of the basics
What is HealthNewsReview.org?
The mission of HealthNewsReview.org is to improve the public dialogue about health care by helping consumers critically analyze claims about health care interventions and by promoting the principles of shared decision-making reinforced by accurate, balanced and complete information about the tradeoffs involved in health care decisions. HealthNewsReview.org evaluates health care journalism, advertising, marketing, public relations and other messages that may influence consumers and provides criteria that consumers can use to evaluate these messages themselves. Improving the quality and flow of health care news and information to consumers can be a significant step towards meaningful health care reform.
Blog
Website
Article : Health News Review
Feb 2 2016
Feb 2 2016
Zepatier (elbasvir and grazoprevir)
In-depth Merck release on new Hep C drug skirts some of the basics
Our Review Summary
Merck’s PR release fills us in on its freshly FDA-approved drug — Zepatier (elbasvir and grazoprevir) — to treat two different forms of hepatitis C and claims to “cure” upwards of 94% of infections based on 12- and 16-week trials. The combination pill is taken once a day throughout treatment. The release seems targeted primarily to healthcare professionals, rather than consumers, so it’s chock-full of jargon and statistics. While the release indicates the risks, benefits and costs, we saw some weaknesses in the presentation of the evidence. For example, the news release did not provide the outcomes for the placebo group, even though the studies compared the drugs with placebo. Nor did it explain that the outcome assessed — sustained virologic response — is a short-term proxy for the longer-term results that patients really care about, such as rates of liver failure and cancer.
Speaking of costs, what this release doesn’t cover (although who would expect a for-profit drug company to do so?) is the insane cost of specialty drugs, the rising demand for them, and their increasing burden on the U.S. healthcare system. HealthNewsReview.org contributor Trudy Lieberman expands on this issue in a recent blog post, which happens to focus on another (very expensive) hepatitis C drug.
Continue reading.....
Related:
Resistance Testing is Recommended Prior to Merck Zepatier Treatment Only for Genotype 1a
Integrating daclatasvir into hepatitis c therapy (pages 1–4)
Omobonike Oloruntoba and Andrew J. Muir
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.524
Watch a video presentation of this article
Watch the interview with the author
Consultations in Hepatology
Guest Edited by Mary Rinella, MD
Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic patients(pages 5–7)
Christopher Moore
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.516
Watch a video presentation of this article
Watch the interview with the author
Integrated Health
Guest Edited by Felix Stickel, MD
Silymarin in the treatment of liver diseases: What is the clinical evidence? (pages 8–10)
Peter Ferenci
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.522
February 2016 Newsletters
HepCBC Hepatitis C Education and Prevention Society
HepCBC’s MONTHLY NEWSLETTER
The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.
February Newsletter
DOWNLOAD
Febuary, 2016 hepc.bull HERE.
ARTICLES IN THIS ISSUE of the HEPC.BULL include:
Take our 20-second "RIBAVIRIN CHALLENGE! - "Comparing Australia's HCV Drug Coverage Policy with Canada's - Treating Older Patients with Newer Drugs - Does it Work? -World Hepatitis Alliance - Merck's "Zepatier" Now FOR SALE (but not yet 'covered') in Canada! - page 1
Services for HCV Patients at AIDS Vancouver Island Combat Stigma - page 2
New York City's Hep C Action Plan Highlights Testing Baby Boomers as Well as Preventing New Cases (in 2013!) - page 3
Stay Connected
Related:
Resistance Testing is Recommended Prior to Merck Zepatier Treatment Only for Genotype 1a
Special Issue: New Treatments for HCV, Consultations in Hepatology, Integrated Health & Emerging Liver Scholars
The journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, review full data articles, and download files in either HTML or PDF formats.
Volume 7, Issue 1 Pages 1 - 20, January 2016
The latest issue of Clinical Liver Disease is available on Wiley Online Library
Reviews
New Treatments for HCV
Guest Edited by Nancy Reau, MDThe journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, review full data articles, and download files in either HTML or PDF formats.
Volume 7, Issue 1 Pages 1 - 20, January 2016
The latest issue of Clinical Liver Disease is available on Wiley Online Library
Reviews
New Treatments for HCV
Integrating daclatasvir into hepatitis c therapy (pages 1–4)
Omobonike Oloruntoba and Andrew J. Muir
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.524
Watch a video presentation of this article
Watch the interview with the author
Consultations in Hepatology
Guest Edited by Mary Rinella, MD
Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic patients(pages 5–7)
Christopher Moore
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.516
Watch a video presentation of this article
Watch the interview with the author
Integrated Health
Guest Edited by Felix Stickel, MD
Silymarin in the treatment of liver diseases: What is the clinical evidence? (pages 8–10)
Peter Ferenci
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.522
Watch a video presentation of this article
Watch the interview with the author
Emerging Liver Scholars
Guest Edited by William Sanchez, MD
Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis(pages 11–14)
Ahmed Akhter, Abhishek Pulla and Adnan Said
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.523
Watch a video presentation of this article
Watch the interview with the author
Social determinants in liver transplantation (pages 15–17)
Joel T. Adler and Heidi Yeh
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.525
Watch a video presentation of this article
Watch the interview with the author
Nutrition, fluid, and electrolytes in chronic liver disease (pages 18–20)
Miguel A. Lalama and Yasser Saloum
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.526
Watch a video presentation of this article
Watch the interview with the author
Watch the interview with the author
Emerging Liver Scholars
Guest Edited by William Sanchez, MD
Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis(pages 11–14)
Ahmed Akhter, Abhishek Pulla and Adnan Said
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.523
Watch a video presentation of this article
Watch the interview with the author
Social determinants in liver transplantation (pages 15–17)
Joel T. Adler and Heidi Yeh
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.525
Watch a video presentation of this article
Watch the interview with the author
Nutrition, fluid, and electrolytes in chronic liver disease (pages 18–20)
Miguel A. Lalama and Yasser Saloum
Article first published online: 29 JAN 2016 | DOI: 10.1002/cld.526
Watch a video presentation of this article
Watch the interview with the author
February 2016 Newsletters
HepCBC’s MONTHLY NEWSLETTER
The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.
February Newsletter
DOWNLOAD
Febuary, 2016 hepc.bull HERE.
ARTICLES IN THIS ISSUE of the HEPC.BULL include:
Take our 20-second "RIBAVIRIN CHALLENGE! - "Comparing Australia's HCV Drug Coverage Policy with Canada's - Treating Older Patients with Newer Drugs - Does it Work? -World Hepatitis Alliance - Merck's "Zepatier" Now FOR SALE (but not yet 'covered') in Canada! - page 1
Services for HCV Patients at AIDS Vancouver Island Combat Stigma - page 2
New York City's Hep C Action Plan Highlights Testing Baby Boomers as Well as Preventing New Cases (in 2013!) - page 3
AbbVie's "Technivie" for Genotype 4; Patient Input Requested - AbbVie's New Genotype 1 "Holkira Pak" Study Now Open - In Memoriam: Jacques Chambers, a Hero to both HCV+ and HIV+ People - New Drug Report Summary from NATAP - Upcoming Conferences - page 4
"Cured and Loving It" - SVR Honour Roll now up to 35 Lucky People! - page 5
Visit or Volunteer at HepCBC Booths at THREE Upcoming Health Fairs in Victoria/Vancouver with Seniors Focus - Current Canadian Drug Pricing Formula Results in Higher Prices Because it Doesn't Consider Number of Patients: ACTION HEPATITIS CANADA's new Policy Paper - page 6
Compensation - Medication Co-Pay Subsidy and Care Programs - page 7
Support Groups/Clinics: in Canada WHERE & WHEN - page 8
"Cured and Loving It" - SVR Honour Roll now up to 35 Lucky People! - page 5
Visit or Volunteer at HepCBC Booths at THREE Upcoming Health Fairs in Victoria/Vancouver with Seniors Focus - Current Canadian Drug Pricing Formula Results in Higher Prices Because it Doesn't Consider Number of Patients: ACTION HEPATITIS CANADA's new Policy Paper - page 6
Compensation - Medication Co-Pay Subsidy and Care Programs - page 7
Support Groups/Clinics: in Canada WHERE & WHEN - page 8
View All Newsletters, Here
Stay Connected
HCV Advocate
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.
February Newsletter
This month’s edition of the HCV Advocate newsletter has the following articles:
In Memory of Jacques Chambers – a member of the HCV Advocate family has died after a brief illness. Read about Jacques and his many contributions to the HCV Advocate and the other communities.
HealthWise—Generic Hepatitis C Drugs –Lucinda K. Porter RN writes about the pros and cons of generic Hep C drugs so you can make an educated choice about whether or not you want to go the generic route.
SnapShots—I write about the influence of gender on HCV disease progression, treatment with sofosbuvir plus daclatasvir to treat people with HIV/HCV coinfection and the prevalence of HIV, HBV and HCV among people with severe mental illness.
HCSP Training Workshops – 2002 – 2015 – the training workshops have come to an end. I write a short recap of our training workshop history including the best and worst of my experiences on the road.
What’s Up – we have updated A Guide to Understanding HCV 2016.
We also discuss changes to our three blogs:
HCV News and Pipeline Blog
HBV Blog
Official Blog of the Hepatitis and Tattoo Website.
Note: If you are currently a Google/Blogger follower, you will no longer be receiving the updates you are used to receiving. We’d like to keep you updated, so please “Follow by Email” on the new blog after February 1; or simply use the old blog address when you want to see the latest posts and you will be redirected.
Click here to read this issue.
View past newsletters here....
Connect With HCV Advocate
Welcome to the January/February 2016 edition of the Liver Lowdown. Click on the links below and check out our featured stories for the month!
Newsletter
January/February
INTRO/FEATURE OF THE MONTH
Happy 2016 and welcome to our first Liver Lowdown newsletter of 2016. This marks our 40th year serving the liver community, so this issue will focus on a topic that is near and dear to us: Research.
READ MORE
LIVER MEETING- INTRO AND NAFLD/NASH NEWS
Americans know little about the liver. See the statistics. On the other hand, scientists are learning more about conditions like Fatty Liver Disease every day.
READ MORE
LIVER MEETING- HEPATITIS C AND HEPATITIS B NEWS
Hepatitis C and Hepatitis B remained popular topics of research and conversation at the AASLD conference.
READ MORE
Hepatitis C and Hepatitis B remained popular topics of research and conversation at the AASLD conference.
READ MORE
Related: Jan 28 2016
LIVER MEETING- PSC AND PBC NEWS
Read more about Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) advancements presented at the Liver Meeting.
READ MORE
LIVER MEETING- LIVER TRANSPLANT NEWS, ADDITIONAL FINDINGS AND CLOSING
Interesting takeaways about liver transplants, cirrhosis and the health benefits of coffee.
READ MORE
CALENDAR OF EVENTS
As we start the new year, we've got a variety of events planned around the country. Find out what's going on near you!
READ MORE
RECIPE OF THE MONTH
Looking for an interesting recipe to try out? We've got you covered, with a vegan and gluten-free option from one of our Flavors chefs that's sure to tantalize your taste buds!
READ MORE
To receive the newsletter when it's "hot off the press" please join our email list.
Check Us Out On Twitter and Facebook
.
NYC Hep C Task Force
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.
Data and information to support advocacy efforts
NYC & NYS Hepatitis Data Reports.
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to work on projects in order to meet needs identified by the community.
Data and information to support advocacy efforts
NYC & NYS Hepatitis Data Reports.
Find NYC and NY State viral hepatitis surveillance data to help with reports, grant applications, advocacy and more!
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
Ann Intern Med, Aug 2015. "Under any financial context, when payers make decisions about HCV treatment, it will be important to consider the ethics and public health implications of prioritizing patients for treatment. The effects of prior approval policies for new HCV treatments on patient outcomes warrant continued investigation."
See more Publications
January 2016 Hep Free NYC Newsletter
See more Publications
January 2016 Hep Free NYC Newsletter
Subscribe to this Newsletter
Join Us
GI & Hepatology News
GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
GI & Hepatology Newsletter
February 2016 PDF ( 4.2MB)
Highlights
Nonalcoholic fatty liver disease will keep rising
Simeprevir plus sofosbuvir held up in real-world HCV study
Factors at VA that could reduce missed appointments
Factors at VA that could reduce missed appointments
View all issues
News
Sovaldi topped Medicare part D spending in 2014
By: RICHARD FRANKI
02/01/16
In its first year on the market, the hepatitis C virus drug Sovaldi soared to the top of the Medicare part D spending list, the Centers for Medicare & Medicaid Services reported.
News
Sovaldi topped Medicare part D spending in 2014
By: RICHARD FRANKI
02/01/16
In its first year on the market, the hepatitis C virus drug Sovaldi soared to the top of the Medicare part D spending list, the Centers for Medicare & Medicaid Services reported.
By: RICHARD PIZZI
01/29/16
The U.S. Food and Drug Administration has approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus genotypes 1 and 4 infections in adults.
Continue reading...
Read breaking news stories now: visit the GI & Hepatology News website.
Stay connected
Read breaking news stories now: visit the GI & Hepatology News website.
Stay connected
HCV Action e-update: January 2016
04 Feb 2016
HCV Action have published two new case studies, both of which highlight innovative ways of ensuring that more people are diagnosed, tested and treated for hepatitis C.
LATEST NEWS FROM THE HEPATITIS C TRUST
Be the voice of people living with hepatitis C
View newsletter archive
Connect With Us On Twitter
Blogs Around The Web
Writing Your HCV StoryLIVING
By Daryl Luster - February 2, 2016
Not all of us feel comfortable sharing our hepatitis c story with the world. There are a number of reasons why people do not disclose their status beyond those close to them,...READ MORE
Step by Step or One Day at a TimeLIVING
By Daryl Luster - January 28, 2016
In history there have been many versions of what these words mean, and here in the context of dealing with HCV we use them also. Several examples can be found in popular... READ MORE
The Power of HopeLIVING
By Daryl Luster - January 25, 2016
On doing a little research before writing this, I was looking into the origins of the word hope, and I learned something. It was said in one account that it was from... READ MORE
Judgment and AcceptanceLIVING
By Daryl Luster - January 14, 2016
As we have all heard many times, and possibly said before, it is wrong to judge others. It is certainly a noble pursuit not to judge, but in reality we do it,... READ MORE
VIEW ALL POSTS BY DARYL LUSTER
Foods that are Good for Your LiverLIVING
By Jenelle Marie Davis - February 4, 2016
Why it Matters? The liver is an incredibly vital organ – so much so that the body cannot survive without it. Two of its primary functions are to work with your blood... READ MORE
Dry Itching Skin SolutionsLIVING
By Karen Hoyt - February 3, 2016
Believe me, I understand that feeling. It is more than just dry skin. It is an itching sensation that can drive you a little bit batty at times. One of the symptoms... READ MORE
Socially accessible
We’re active on your social network.
HEPATITISC.NET ON TWITTER
HEPATITISC.NET ON FACEBOOK
HEPATITISC.NET ON GOOGLE+
About Karen Hoyt
Karen Hoyt offers a no nonsense approach to living with Cirrhosis. A Hepatitis C treatment survivor, she created a liver loving diet and lifestyle that allows her to create awareness and advocate for her Best Friends at http://www.ihelpc.com
During my battle with liver cancer, I loved reading all of your personal cards, emails, and messages. How could I possibly respond back? (Picture me typing all night.) Instead, I folded strong words into my heart and recited them to me when I needed them. (Daily, hourly) Little love letters.One morning after my liver transplant, while poring over more of your emails and messages, one word kept popping up – Brave. I remember my face felt hot. I didn’t feel brave at all. I was terrified. I needed courage and confidence with liver cancer.
Continue reading....
The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure for hepatitis B and helping to improve the lives of those affected worldwide through research, education and patient advocacy. Visit www.hepb.org
Can People with HBeAg-Negative Hepatitis B Ever Stop Taking Antivirals?
Posted on February 3, 2016
Medical guidelines suggest that individuals with HBeAg-negative hepatitis B with signs of liver damage face an “indefinite” or even lifetime commitment to taking daily antiviral pills.In this week’s blog, we explore when—if ever—individuals with hard-to-treat HBeAg-negative hepatitis B can ever stop taking antivirals.
Creating a World Free of Hepatitis C
Welcome to my website and blog. My name is Lucinda Porter and I am a nurse committed to raising awareness about hepatitis C. I believe that we can create a world free of hepatitis C. We do this together, one step at a time.
World Cancer Day: Curing Hep C is One Way to Prevent Liver Cancer
by LUCINDA PORTER on FEBRUARY 4, 2016
My Hep C Travel Diary, Hepatitis C Advocate
Access to Hepatitis C Treatment for Everyone
February 2, 2016
I am not writing in my blog as regularly as previously because most of my time is now divided between doing my PhD at the University of Tasmania and helping people around the world get access to affordable Hepatitis C treatment. With the Australian government making Hep C medicines available with a subsidy on the PBS (Pharmaceutical Benefits Scheme) demand for my assistance in Australia has reduced significantly but not entirely. This has enabled me to focus on helping people with Hep C around the world access generic Hep C treatments.Access to Hepatitis C Treatment for Everyone
February 2, 2016
Continue reading...
Matt Starr
Hepatitis, Liver Disease Support Coach
Deep Roots, Living with Hepatitis C
February 2, 2016
What does it mean to be well? For many of us, we consider being well as a physical state. When we are younger or living without chronic pain disease or illness, it means having a strong, graceful body. And yes, being strong and fit is a good thing. It is a narrow definition, however, of what it means to be really well.
Author, Hepatitis C Advocate, Health Educator
Zepatier: The Newest Hepatitis C Drug
February 1, 2016
Zepatier: The Newest Hepatitis C Drug
February 1, 2016
Welcome to Zepatier, the newest FDA-approved medicine to treat hepatitis C. Zepatier is manufactured by Merck. The wholesale acquisition cost was set at a very competitive price of $54,600 for 12 weeks of Zepatier.
A story about living with hep C, fatigue, anemia cirrhosis and more...
February 5, 2016
I acquired the hepatitis C virus in 1988 from a blood transfusion needed after a C-section. In 1995, I did the interferon treatment with negative results. In the late 1990s, I tried treatment again. I was treated with interferon and ribavirin, but was unable to complete therapy due to a drastic drop in white blood cells. For quite some time, I received Neupogen injections to stimulate white cell production. Eventually I was listed for a liver transplant at the University of Miami.
Continue reading...
As I travel the country training people, I see the lack of education about HCV, both from patients, as well as doctors, particularly in rural areas. This is why I now call them Educational Support Groups.
Connect With Us On Twitter and Facebook
Where to go to find useful information about hepatitis C
I am frequently asked by patients to provide them with the best online resources on hepatitis C so they can review information on their own. The world of hepatitis C online information is enormous and not all of it is helpful. Some may actually provide some misinformation. I would generally tend to avoid sites maintained by a non-health care provider, although I do know one that provides excellent nutrition information, for example.
I am frequently asked by patients to provide them with the best online resources on hepatitis C so they can review information on their own. The world of hepatitis C online information is enormous and not all of it is helpful. Some may actually provide some misinformation. I would generally tend to avoid sites maintained by a non-health care provider, although I do know one that provides excellent nutrition information, for example.
Related:
Hepatitis C Links
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences and more.
WHY HCV SUPPORT GROUPS ARE STILL NECESSARY
1/20/2016
Ronni Marks, Founder/ ED of HCMSG/ Patient Advocate
I have heard lately that some doctors and others are questioning if there is still a need for HCV support groups. While I agree these groups are no longer needed for hand holding purposes as they were in the interferon era, they now have taken on a new look. These are some of the reasons I believe there is still a very important role for educational support groups.These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences and more.
WHY HCV SUPPORT GROUPS ARE STILL NECESSARY
1/20/2016
Ronni Marks, Founder/ ED of HCMSG/ Patient Advocate
As I travel the country training people, I see the lack of education about HCV, both from patients, as well as doctors, particularly in rural areas. This is why I now call them Educational Support Groups.
Enjoy the weekend!
Tina
Tina
No comments:
Post a Comment